Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position


Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Continue reading here:
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position

Related Posts